Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (281-290 of 344) with videos related to

Pageof 35
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2025
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 StudyKohei Shitara, Sun Young Rha, Lucjan Wyrwicz, et al.
Lancet (London, England)|June 9, 2018
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
Lancet (London, England)|April 17, 2023
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Florian Lordick, Yung-Jue Bang, et al.
Lancet (London, England)|October 23, 2023
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialYelena Y Janjigian, Akihito Kawazoe, Yuxian Bai, et al.
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 18, 2020
Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancerAkinori Sasaki, Yoshiaki Nakamura, Yosuke Togashi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trialCharles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 StudyKeun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal for Immunotherapy of Cancer|June 5, 2023
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockadeGiovanni Randon, Yu Aoki, Romain Cohen, et al.
Journal for Immunotherapy of Cancer|February 9, 2024
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancerShogo Takei, Yosuke Tanaka, Yi-Tzu Lin, et al.
Pageof 35

Showing results (281-290 of 344) with videos related to

Sort By:
Pageof 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2025
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 StudyKohei Shitara, Sun Young Rha, Lucjan Wyrwicz, et al.
Lancet (London, England)|June 9, 2018
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
Lancet (London, England)|April 17, 2023
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Florian Lordick, Yung-Jue Bang, et al.
Lancet (London, England)|October 23, 2023
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialYelena Y Janjigian, Akihito Kawazoe, Yuxian Bai, et al.
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 18, 2020
Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancerAkinori Sasaki, Yoshiaki Nakamura, Yosuke Togashi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trialCharles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 StudyKeun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal for Immunotherapy of Cancer|June 5, 2023
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockadeGiovanni Randon, Yu Aoki, Romain Cohen, et al.
Journal for Immunotherapy of Cancer|February 9, 2024
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancerShogo Takei, Yosuke Tanaka, Yi-Tzu Lin, et al.
Pageof 35